Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (pilot cohort study with short walking objectives) - PERIPATEI

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502018-10-00

Acronym

RBHP 2022 DUALE

Enrollment

Registered

2023-01-18

Start date

2023-11-07

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic osteoarthritis of the hip or knee

Brief summary

For a given individual, the main criterion is the success of the therapeutic program, defined by an increase of at least 30% in the monthly number of target movements compared to the month of basal observation, in the absence of treatment discontinuation. NSAIDs for intolerance

Interventions

DRUGFLECTOR 50 mg

DRUGcomprimé

DRUGNIFLURIL 250 mg

DRUGgélule

DRUGDOLIPRANE 1000 mg

DRUGcomprimé effervescent sécable

DRUGIBUPROFENE ARROW 200 mg

DRUGcomprimé enrobé

DRUGLANSOPRAZOLE MYLAN PHARMA 15 mg

DRUGgélule gastro-résistante

DRUGPROFENID 50 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
For a given individual, the main criterion is the success of the therapeutic program, defined by an increase of at least 30% in the monthly number of target movements compared to the month of basal observation, in the absence of treatment discontinuation. NSAIDs for intolerance	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026